36.80 0.00 (0.00%)
After hours: 6:35PM EDT
|Bid||36.80 x 2400|
|Ask||37.00 x 500|
|Day's Range||36.60 - 36.89|
|52 Week Range||31.67 - 39.43|
|PE Ratio (TTM)||10.46|
|Forward Dividend & Yield||1.36 (3.74%)|
|1y Target Est||N/A|
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision.
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
Pfizer Inc. said early Monday that the Food and Drug Administration failed to approve its trastuzumab biosimilar, intended as a lower-cost version of Roche's cancer drug Herceptin. The FDA asked for more ...
Moody's Investors Service, ("Moody's") has assigned a Ba1 corporate family rating (CFR) and Ba1-PD probability of default rating to NMC Health plc (NMC), the largest healthcare provider in the ...
How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business demonstrates that major consumer companies remain hungry for health-related products. The fragmented nature of the sector and its appeal to younger consumers makes further M&A activity a likely prospect even after a spate of recent acquisitions. The U.S.-based maker of Tide detergent and Gillette razors announced its plan on Thursday to buy Merck brands such as Seven Seas vitamins.
Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products. Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
Spark Therapeutics (ONCE) generated revenue of $12 million in 2017 compared to $20.1 million in 2016. Under this collaboration, Spark Therapeutics maintains the responsibility for developing SPK-FIX candidates through Phase 1 and 2 trials. In November 2017, this agreement was amended, and Spark received a $10 million up-front payment and was eligible to receive an additional $15 million.
Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.
Let’s call a spade a spade. Turnaround stocks are fun. They’re even more fun when you’re able to say you bought them at — or at least near — their low because you understood the underlying story better than most other investors did.